1059 related articles for article (PubMed ID: 25503144)
1. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
[TBL] [Abstract][Full Text] [Related]
2. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
3. Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score.
De Luca S; Passera R; Milillo A; Coda R; Randone DF
BJU Int; 2012 Dec; 110(11 Pt B):E778-82. PubMed ID: 23116408
[TBL] [Abstract][Full Text] [Related]
4. Pathological patterns of prostate biopsy in men with fluctuations of prostate cancer gene 3 score: a preliminary report.
De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Porpiglia F
Anticancer Res; 2015 Apr; 35(4):2417-22. PubMed ID: 25862908
[TBL] [Abstract][Full Text] [Related]
5. Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies.
De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Milillo A; Papotti M; Porpiglia F
BJU Int; 2014 Dec; 114(6b):E56-E61. PubMed ID: 24472071
[TBL] [Abstract][Full Text] [Related]
6. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
[TBL] [Abstract][Full Text] [Related]
7. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
[TBL] [Abstract][Full Text] [Related]
8. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
[TBL] [Abstract][Full Text] [Related]
9. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
[TBL] [Abstract][Full Text] [Related]
10. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
12. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
Ferro M; Bruzzese D; Perdonà S; Marino A; Mazzarella C; Perruolo G; D'Esposito V; Cosimato V; Buonerba C; Di Lorenzo G; Musi G; De Cobelli O; Chun FK; Terracciano D
PLoS One; 2013; 8(7):e67687. PubMed ID: 23861782
[TBL] [Abstract][Full Text] [Related]
13. Effect of NIH-IV prostatitis on free and free-to-total PSA.
Stancik I; Lüftenegger W; Klimpfinger M; Müller MM; Hoeltl W
Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
[TBL] [Abstract][Full Text] [Related]
14. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
15. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients.
Goode RR; Marshall SJ; Duff M; Chevli E; Chevli KK
Prostate; 2013 Jan; 73(1):48-53. PubMed ID: 22585386
[TBL] [Abstract][Full Text] [Related]
16. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
van Vuuren SP; Heyns CF; Zarrabi AD
BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
[TBL] [Abstract][Full Text] [Related]
17. [Aggressiveness and extent of prostatic inflammation relates with serum PSA levels in type IV prostatitis].
Man LB; Li GZ; Huang GL; Wang JW; Liu BY
Zhonghua Nan Ke Xue; 2012 Aug; 18(8):710-4. PubMed ID: 22934516
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
19. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
20. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]